Fig. 5.

Receptor-ligand pharmacophore generation for ENT1. (A) Common Feature generation using receptor-ligand pharmacophore generation using dilazep and analogs. (B) Mimicry of common features found in crystal structure by filtering all generated pharmacophores from receptor-ligand pharmacophore generation to match actual interactions. (C) Common feature pharmacophore created using a sampling of strong, weak, and very weak inhibitors. (D) In a similar manner described above, the full pharmacophore generated from receptor-ligand pharmacophore generation was made to mimic the pharmacophores found in the common pharmacophore generation step.